J&J's Antipsychotic Franchise May Be "Invega"rated On Dec. 20
This article was originally published in The Pink Sheet Daily
Executive Summary
Risperdal follow-on's trade name is revealed; paliperidone will get a short re-review from FDA, company says.
You may also be interested in...
Antipsychotic Marketing Investigation Broadens
Pfizer and Lilly join AstraZenenca under California attorney general’s microscope for marketing practices related to antipsychotics.
J&J’s Paliperidone Will Not Need Additional Studies
The company plans to submit its response to FDA’s “approvable” letter by the end of the month.
Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy
While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.